Sage Therapeutics Refines Pipeline Development Efforts To Advance SAGE-718 & SAGE-324, As Well As Pause Certain Earlier-stage Programs
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics is refining its pipeline development efforts to advance SAGE-718 & SAGE-324, while pausing certain earlier-stage programs. Chris Benecchi will oversee Medical Affairs following the departure of Mark Pollack. The company expects annualized net savings of approximately $240 million, 60% of which is related to R&D.
August 31, 2023 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sage Therapeutics is advancing SAGE-718 & SAGE-324 and expects to save $240 million annually, mostly from R&D. This could potentially boost the company's financial performance.
The advancement of SAGE-718 & SAGE-324 and the expected savings from R&D could potentially improve Sage Therapeutics' financial performance, which could positively impact the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100